Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 85,712

Document Document Title
WO/2018/169027A1
Disclosed is a hardly water-soluble phytochemical absorption promoter capable of significantly increasing the speed and/or amount of the intake of a phytochemical into the body, in particular, the transition thereof into the blood. A lac...  
WO/2018/168997A1
The purpose of the present invention is to provide an oral composition that possesses an excellent teeth remineralization promoting effect and that is capable of effectively promoting teeth remineralization even when retained in the oral...  
WO/2018/166298A1
The present invention provides an immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic pharmaceutical composition comprising at least an antigen and the above-...  
WO/2018/170167A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/170166A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/168407A1
Provided are: a composition for inhibiting the growth of a bacterium having a menaquinone synthesis pathway through futalosine or a futalosine derivative, said composition comprising as an active ingredient a fatty acid which carries 18 ...  
WO/2018/168821A1
The purpose of the present invention is to provide a novel composition for use in the oral cavity, in particular a composition for use in the oral cavity that is effective in inhibiting the adhesion of periodontal disease bacteria to ani...  
WO/2018/170133A1
The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) ...  
WO/2018/170165A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/170389A1
Provided herein are compositions comprising nicotinamide riboside and optionally pterostilbene, for use in treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to th...  
WO/2018/169011A1
Provided are a food composition for improving an intestinal flora balance and an intestinal flora balance improving agent, each of which contains a euglena-derived substance as an active ingredient. The present invention can be solved by...  
WO/2018/169055A1
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...  
WO/2018/167283A1
The present invention relates to the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDA) associated neural remodeling (PANR). The inventors investigated the effects of the stromal compartment on PDA and PANR and the specifi...  
WO/2018/166404A1
Celastrol or pharmaceutically acceptable salts thereof, and applications thereof in preparing a medicament for preventing and/or treating a cholestatic liver disease or liver fibrosis  
WO/2018/170182A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/165726A1
The present invention relates to a composition comprising the alcoholic extract of the jabuticaba fruit skin (Myrciaria caulifolia) for use in the treatment of metabolic processes, such as weight loss and/or reduction of weight gain, as ...  
WO/2018/169063A1
Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog...  
WO/2018/170390A1
Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some inst...  
WO/2018/169742A1
Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treatment of non-alcoholic steatohepatitis, alcoholic hepatitis, pulmonary arterial hypertension, heart failure with preserved ejection fracti...  
WO/2018/165707A1
The present invention relates to improved phosphopeptide stabilised amorphous calcium phosphate and/or amorphous calcium fluoride phosphate complexes and compositions containing those complexes. Methods of making the complexes of the inv...  
WO/2018/165936A1
Polypeptide for regulating energy metabolism and uses thereof in the preparation of drugs for treating diseases related to abnormal energy metabolism. The polypeptide can reduce fat absorption, can reduce fat accumulation in a liver and ...  
WO/2018/161507A1
A novel low-toxicity tripterygium glycoside, being obtained by chemical processing tripterygium glycoside and adding triptriolide. The novel low-toxicity tripterygium glycoside can effectively alleviate renal pathological damage and prot...  
WO/2018/165581A1
The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, t...  
WO/2018/162551A1
A composition comprising resveratrol and polymyxins for use for the treatment of urinary tract infections (UTI), for use for intestinal decontamination, for use for the treatment of bacterial intestinal infectious disease, and low tract ...  
WO/2018/163119A1
The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.  
WO/2018/163163A1
A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract compri...  
WO/2018/165250A1
The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I): (Formula (I)) where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising...  
WO/2018/164228A1
The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition c...  
WO/2018/159522A1
Provided is a food composition for preventing or alleviating metabolic syndrome, the food composition containing, as active ingredients, a 67 kDa laminine receptor (67LR) agonist and a sulfur-containing compound found from an allium plan...  
WO/2018/160406A1
The present invention provides a compound of Formula I I wherein X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of and; or a pharmaceutic...  
WO/2018/159431A1
The purpose of the present invention is to provide a novel therapeutic agent for liver disease. The present invention is a mesenchymal stem cell characterized by high expression of the tissue factor pathway inhibitor (TFPI). It is prefer...  
WO/2018/159808A1
The present invention provides: an antibody-drug conjugate of an anti-IL-7R antibody; and a pharmaceutical composition for treating cancer or inflammation and containing an antibody-drug conjugate of an anti-IL-7R antibody and a cytotoxi...  
WO/2018/160981A1
The invention provides compositions comprising chitosan, manuka honey and one or more additional components that promotes digestive health (e.g., inulin, probiotics) for the treatment and prevention of gastric ulcers (esophageal, stomach...  
WO/2018/158459A1
The invention relates to an orodispersible tablet that is characterized in that said orodispersible tablet comprises burlulipase. The invention further relates to liquid pharmaceutical compositions that contain solutions of such orodispe...  
WO/2018/160739A1
Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.  
WO/2018/157857A1
Provided are an amide derivative inhibitor, a preparation method and an application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor and a pharmaceutica...  
WO/2018/157233A1
A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT7 receptor (5-HT7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injecti...  
WO/2018/157900A1
The invention relates to a method and composition for modulating the microbiota in the gastro‐intestinal tracts of non‐infant humans, particularly for increasing the abundance of Bifidobacterium longum and/or Bifidobacterium bifidum ...  
WO/2018/157730A1
The present invention relates to a urea-substituted aromatic ring-linked dioxane-quinazoline compound of formula (1) and a urea-substituted aromatic ring-linked dioxane-quinoline, or a pharmaceutically acceptable salt thereof or a hydrat...  
WO/2018/161028A1
Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrog...  
WO/2018/160510A1
Method and composition for treating eating disorders in humans and veterinary animals by administering a composition including: (i) mirtazapine, (ii) a cannabis compound and (iii) a fat-soluble vitamin.  
WO/2018/157190A1
The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human sub...  
WO/2018/159714A1
The present invention addresses the problem of providing a sugar and/or lipid metabolism-improving agent. The problem is solved by a sugar and/or lipid metabolism-improving agent that contains fibrous paramylon.  
WO/2018/158284A1
The present invention relates to a method for producing a stabilized microbiome sample, a compression-cooling device for providing a stabilized microbiome sample and a stabilized microbiome sample, in particular for use in a method for t...  
WO/2018/159787A1
[Problem] The purpose of the present invention is to provide: a method for making an animal that has been stressed, and, in particular, chronically stressed, contract or present a specific disease or symptoms; and a tool that, by elucida...  
WO/2018/158465A1
The invention relates to a pharmaceutical composition comprising pancreatin which has a coating containing at least one lipase. Preferably, the least one lipase is burlulipase. The invention also relates to medicaments comprising one suc...  
WO/2018/159546A1
The present invention addresses the problem of providing an exceptional GLP-1 secretagogue that is a component derived from milk, a composition for promoting GLP-1 secretion, and a food/beverage or drug containing the same. Any selected ...  
WO/2018/159852A1
The purpose of the present invention is to provide a curcumin-containing solid composition which can be used as a composition for treatment or prevention of disorders or symptoms in which intracellular absorption of curcumin is beneficia...  
WO/2018/155660A1
Provided is a novel use of dead cell bodies of a lactic acid bacterium. A novel use of dead cell bodies of a lactic acid bacterium can be discovered by selecting an optimal lactic acid bacterium and selecting an optimal additive.  
WO/2018/155692A1
The invention provides anti-HLA-DQ2.5/8 antibodies and methods of using the same. The antibodies of the present invention have binding activity to human HLA-DQ2.5/8 and monkey MHC-DQ, but substantially no binding activity to HLA-DR, HLA-...  

Matches 1 - 50 out of 85,712